CELC NASDAQ
Celcuity Inc.
1W: -10.1%
1M: -17.5%
3M: -34.4%
YTD: -18.0%
1Y: +498.8%
3Y: +682.4%
5Y: +282.5%
$82.46
+0.19 (+0.23%)
Weekly Expected Move ±12.6%
$62
$72
$83
$93
$103
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.0B
52W Range34.3-151.02
Volume1,771,872
Avg Volume1,621,219
Beta0.16
Dividend—
Analyst Ratings
Company Info
CEOBrian F. Sullivan
Employees155
SectorHealthcare
IndustryBiotechnology
IPO Date2017-09-19
Websitecelcuity.com
2800 Campus Drive
Minneapolis, MN 55446
US
Minneapolis, MN 55446
US
763 392 0767
About Celcuity Inc.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Latest News
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
Celcuity falls as rollout concerns overshadow FDA approval of breast cancer drug
Celcuity gains approval of breast cancer therapy gedatolisib
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
What's Going On With Celcuity Stock On Tuesday?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | S-Sale | 261,368 | $102.50 | 2026-07-14 |
| BAKER BROS. ADVISORS | S-Sale | 2,838,632 | $102.50 | 2026-07-14 |
| Murphy Polly A. | A-Award | 1,530 | — | 2026-06-05 |
| Dalvey David | A-Award | 1,530 | — | 2026-06-05 |
| ROMP CHARLES R | A-Award | 1,530 | — | 2026-06-05 |